Acadian Asset Management LLC decreased its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 18.0% during the 4th quarter, HoldingsChannel reports. The fund owned 1,481,597 shares of the medical research company’s stock after selling 325,471 shares during the quarter. Acadian Asset Management LLC’s holdings in PRA Health Sciences were worth $134,929,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares in the last quarter. Carroll Financial Associates Inc. raised its holdings in PRA Health Sciences by 127.4% during the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after purchasing an additional 790 shares in the last quarter. Comerica Bank acquired a new stake in PRA Health Sciences during the third quarter worth approximately $214,000. Trustmark National Bank Trust Department acquired a new stake in PRA Health Sciences during the second quarter worth approximately $225,000. Finally, Vident Investment Advisory LLC acquired a new stake in PRA Health Sciences during the third quarter worth approximately $247,000. 98.23% of the stock is currently owned by hedge funds and other institutional investors.

PRAH has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Mitsubishi UFJ Financial Group initiated coverage on shares of PRA Health Sciences in a report on Friday, December 15th. They set an “overweight” rating and a $102.00 price objective on the stock. Credit Suisse Group reissued an “outperform” rating and set a $90.00 price objective (up previously from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. BidaskClub raised shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Finally, Mizuho initiated coverage on shares of PRA Health Sciences in a report on Thursday, September 21st. They set a “buy” rating and a $82.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $91.85.

In other news, Director Matthew P. Young sold 5,115 shares of PRA Health Sciences stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David W. Dockhorn sold 72,850 shares of PRA Health Sciences stock in a transaction on Friday, December 28th. The shares were sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the completion of the transaction, the executive vice president now directly owns 72,850 shares in the company, valued at $6,616,965.50. The disclosure for this sale can be found here. Insiders sold a total of 150,815 shares of company stock worth $13,642,620 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Shares of PRA Health Sciences Inc (PRAH) traded up $1.73 during trading on Thursday, hitting $92.10. 327,300 shares of the stock were exchanged, compared to its average volume of 438,718. The firm has a market cap of $5,850.00, a PE ratio of 51.74, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41. PRA Health Sciences Inc has a fifty-two week low of $54.08 and a fifty-two week high of $92.84. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.03. The business had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 EPS. equities analysts expect that PRA Health Sciences Inc will post 3.2 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2018/01/18/acadian-asset-management-llc-has-134-93-million-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.